Related Experiment Videos
Carbimazole and exercise tolerance in chronic airflow obstruction
Thorax
|January 1, 1982
Summary
Carbimazole did not improve exercise tolerance in patients with severe airflow obstruction, despite lowering thyroid hormone levels. This study found no symptomatic or objective benefit, questioning its use in chronic obstructive pulmonary disease (COPD).
Area of Science:
- Pulmonary Medicine
- Endocrinology
Background:
- Severe dyspnoea and chronic airflow obstruction significantly impair quality of life.
- Thyroid dysfunction can influence respiratory and exercise capacity.
Purpose of the Study:
- To investigate the effect of carbimazole on exercise tolerance in patients with severe airflow obstruction.
- To assess if reducing thyroid hormone levels improves symptoms and objective measures in COPD patients.
Main Methods:
- Randomised, double-blind, crossover trial comparing carbimazole 80 mg daily with placebo for two months.
- Monthly assessments included thyroid function, lung function (FEV1, FVC, TLC, KCO), and exercise tolerance (12-minute walking distance, cycle ergometry).
Main Results:
- Carbimazole significantly reduced free thyroxine index (FTI) by 28% compared to placebo.
- No significant differences were observed in 12-minute walking distance, perceived exertion, dyspnoea grade, or resting blood gas tensions.
- Exercise testing revealed no improvement in ventilation, heart rate, blood gases at exhaustion, or work done with carbimazole.
Conclusions:
- Reducing thyroid hormone levels with carbimazole does not offer symptomatic or objective benefits for exercise tolerance in severe airflow obstruction.
- The findings do not support the use of carbimazole for managing chronic airflow obstruction or improving exercise capacity in this patient group.